title: Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer.
abstract: Dose limiting systemic toxicity prevents sufficient exploitation of the steep dose response relationship of most anticancer agents. In our rat liver tumour model (the CC531 colorectal carcinoma), isolated liver perfusion allows administration of higher doses of mitomycin C than hepatic artery infusion, while systemic toxicity remains minimal. To determine the temporal pattern of mitomycin C induced cytokinetic changes, we analysed flow cytometric DNA histograms of CC531 liver tumours from rats treated with high dose mitomycin C (3.2 mg kg-1) via hepatic artery infusion and sacrificed at different time intervals after treatment. Between 12 and 36 h after treatment, the fraction of cells in late S and G2/M phase had markedly increased. The effects of administration of the respective maximally tolerated doses of mitomycin C in isolated liver perfusion and via hepatic artery infusion on progression of tumour cells through the cell cycle and on gross tumour growth were compared. Isolated liver perfusion with mitomycin C resulted in a significant increase in the proportion of cells in mid and late S, and in some accumulation of cells in early S and G2/M phase at 24 and 48 h after treatment. In contrast, after hepatic artery infusion a significant increase of the fraction of cells in G2/M phase was observed at 24 h after treatment. Monitoring tumour growth after isolated liver perfusion five out of seven rats showed a complete tumour remission, while after hepatic artery infusion only a minimal growth delay was detected. This study demonstrates that isolated liver perfusion in the rat CC531 liver tumour model allows the administration of a well-tolerated dose of mitomycin C being high enough to induce a marked DNA synthesis inhibition and even complete tumour remission.
authors.affiliation: Department of Surgery, University Hospital, Leiden, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Marinelli
authors.forename: F R
authors.initials: FR
authors.lastname: Dijkstra
authors.forename: J H
authors.initials: JH
authors.lastname: van Dierendonck
authors.forename: P J
authors.initials: PJ
authors.lastname: Kuppen
authors.forename: C J
authors.initials: CJ
authors.lastname: Cornelisse
authors.forename: C J
authors.initials: CJ
authors.lastname: van de Velde
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis; D006499:Hepatic Artery; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use; D010477:Perfusion; D051381:Rats
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008937:Mitomycins; D016685:Mitomycin